fluorouracil has been researched along with Sarcopenia in 12 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Sarcopenia: Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 7.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| "Consecutive patients with locally advanced (T2 ≥ 4 cm-T4 or N+) anal cancer scheduled for two cycles of concomitant 5-fluorouracil and mitomycin C chemotherapy were selected from an institutional database (n = 106)." | 4.02 | Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer. ( Johnsson, A; Nilsson, MP; Scherman, J, 2021) |
| " The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer." | 3.88 | The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018) |
| "Sarcopenia was present in 38 patients (50." | 1.91 | Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer. ( Bianchini, D; Esposito, L; Foca, F; Frassineti, GL; Gallio, C; Molinari, C; Montanari, D; Monti, M; Morgagni, P; Passardi, A; Prochowski Iamurri, A; Ruscelli, S; Vittimberga, G, 2023) |
| "Sarcopenia was diagnosed in thirty-three (48 %) subjects." | 1.62 | The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy. ( Ichikawa, H; Iwasa, Y; Iwashita, T; Mita, N; Shimizu, M; Shiraki, M; Uemura, S, 2021) |
| "On the other hand, sarcopenia is one of the important prognostic factors of pancreatic cancer." | 1.51 | Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. ( Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Kubota, K; Kurita, Y; Nakajima, A; Tokuhisa, M, 2019) |
| "Sarcopenia was defined as SMI ≤38." | 1.51 | Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019) |
| " This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value." | 1.43 | Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016) |
| "Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy." | 1.42 | Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015) |
| "Sarcopenia was present in 30% (6/20) of patients with reduction in tumor size posttreatment, and in 52% (14/27) of patients with increased tumor size (P = 0." | 1.38 | Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. ( Baracos, VE; Fu, S; Hong, D; Kurzrock, R; Parsons, HA; Pontikos, M; Tsimberidou, AM; Wen, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Monti, M | 1 |
| Prochowski Iamurri, A | 1 |
| Bianchini, D | 1 |
| Gallio, C | 1 |
| Esposito, L | 1 |
| Montanari, D | 1 |
| Ruscelli, S | 1 |
| Molinari, C | 1 |
| Foca, F | 1 |
| Passardi, A | 1 |
| Vittimberga, G | 1 |
| Morgagni, P | 1 |
| Frassineti, GL | 1 |
| Uemura, S | 1 |
| Iwashita, T | 1 |
| Ichikawa, H | 1 |
| Iwasa, Y | 1 |
| Mita, N | 1 |
| Shiraki, M | 1 |
| Shimizu, M | 1 |
| Rinninella, E | 1 |
| Strippoli, A | 1 |
| Cintoni, M | 1 |
| Raoul, P | 1 |
| Vivolo, R | 1 |
| Di Salvatore, M | 1 |
| Genco, E | 1 |
| Manfredi, R | 1 |
| Bria, E | 1 |
| Tortora, G | 1 |
| Gasbarrini, A | 1 |
| Pozzo, C | 1 |
| Mele, MC | 1 |
| Nilsson, MP | 1 |
| Johnsson, A | 1 |
| Scherman, J | 1 |
| Miyata, H | 1 |
| Sugimura, K | 1 |
| Motoori, M | 1 |
| Fujiwara, Y | 1 |
| Omori, T | 1 |
| Yanagimoto, Y | 1 |
| Ohue, M | 1 |
| Yasui, M | 1 |
| Miyoshi, N | 1 |
| Tomokuni, A | 1 |
| Akita, H | 1 |
| Kobayashi, S | 1 |
| Takahashi, H | 1 |
| Yano, M | 1 |
| Williams, GR | 1 |
| Deal, AM | 1 |
| Shachar, SS | 1 |
| Walko, CM | 1 |
| Patel, JN | 1 |
| O'Neil, B | 1 |
| McLeod, HL | 1 |
| Weinberg, MS | 1 |
| Choi, SK | 1 |
| Muss, HB | 1 |
| Sanoff, HK | 1 |
| Kurita, Y | 1 |
| Kobayashi, N | 1 |
| Tokuhisa, M | 1 |
| Goto, A | 1 |
| Kubota, K | 1 |
| Endo, I | 1 |
| Nakajima, A | 1 |
| Ichikawa, Y | 1 |
| Vashi, PG | 1 |
| Gorsuch, K | 1 |
| Wan, L | 1 |
| Hill, D | 1 |
| Block, C | 1 |
| Gupta, D | 1 |
| Jung, HW | 1 |
| Kim, JW | 1 |
| Kim, JY | 1 |
| Kim, SW | 1 |
| Yang, HK | 1 |
| Lee, JW | 1 |
| Lee, KW | 1 |
| Kim, DW | 1 |
| Kang, SB | 1 |
| Kim, KI | 1 |
| Kim, CH | 1 |
| Kim, JH | 1 |
| Tan, BH | 1 |
| Brammer, K | 1 |
| Randhawa, N | 1 |
| Welch, NT | 1 |
| Parsons, SL | 1 |
| James, EJ | 1 |
| Catton, JA | 1 |
| Chemama, S | 1 |
| Bayar, MA | 1 |
| Lanoy, E | 1 |
| Ammari, S | 1 |
| Stoclin, A | 1 |
| Goéré, D | 1 |
| Elias, D | 1 |
| Raynard, B | 1 |
| Antoun, S | 1 |
| Parsons, HA | 1 |
| Tsimberidou, AM | 1 |
| Pontikos, M | 1 |
| Fu, S | 1 |
| Hong, D | 1 |
| Wen, S | 1 |
| Baracos, VE | 1 |
| Kurzrock, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab[NCT01164215] | Phase 1 | 76 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Trimodal Prehabilitation in Pancreatic Cancer Patients Candidate to Neoadjuvant Treatment: A Pilot Study[NCT05722223] | 10 participants (Anticipated) | Interventional | 2022-03-15 | Recruiting | |||
| The Effect of Nutrition for the Colorectal Cancer Patients Receiving Chemotherapy-randomized Controlled Study[NCT04567459] | 100 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for fluorouracil and Sarcopenia
| Article | Year |
|---|---|
Association between Pre-Treatment Biological Indicators and Compliance to Neoadjuvant/Perioperative Chemotherapy in Operable Gastric Cancer.
Topics: Environmental Biomarkers; Fluorouracil; Humans; Neoadjuvant Therapy; Oxaliplatin; Sarcopenia; Stomac | 2023 |
The impact of sarcopenia and decrease in skeletal muscle mass in patients with advanced pancreatic cancer during FOLFIRINOX therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorour | 2021 |
Body Composition Changes in Gastric Cancer Patients during Preoperative FLOT Therapy: Preliminary Results of an Italian Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Combined Modality | 2021 |
Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chem | 2021 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Ci | 2017 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2018 |
Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Ch | 2015 |
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine | 2015 |
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition | 2016 |
Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2012 |